Biocompatible nanomaterials are key components of novel approaches to addressing the major
problems of disease diagnosis and therapy. We have developed several nanoplatforms that offer
potential for significant improvements in multi-modal imaging and targeted delivery of therapeutics.
Magnetic liposomal nanoplatforms for theranostics combine multiple functionalities including imaging,
magnetic targeting to the disease site, delivery of the drug payload through sustained as well as
triggered drug release. We have demonstrated in vivo multimodal imaging using MRI, SPECT and FMT
using these nanoplatforms.
We have developed a new approach to local chemoradiation therapy (CRT), termed Biological In-Situ
Image Guided Radiation Therapy, that involves the coating of spacers routinely used during radiation
therapy with nanoparticles that release radiosensitizing drugs (e.g. docetaxel DTX for Prostate Cancer),
that is synchronized with the radiation therapy schedule, with almost no systemic toxicity. This new
nanoparticle approach is an exciting new combinatorial therapy for cancer as well as other diseases
where image-guided radiation therapy is currently a preferred choice of treatment.